March 1, 2021 5:04pm

As sentiment was boosted by of Johnson & Johnson’s (JNJ) advisory panel approval

While the $1.9 trillion fiscal aid/stimulus bill after a House narrow approval now moves to the Senate which expects to propose amendments

Pre-open indication results: 8 HITs and 2 MISS


The Dow closed UP +603.14 points (+1.95%); the S&P closed UP +90.67 points (+2.38%) while the Nasdaq closed UP +396.48 points (+3.01%)



Indexes jumped sharply on Monday as Treasury yields retreated…

Sector breadth was strong on Monday with only about 6 stocks trading lower of the 35 covered.

On the stimulus front, the House passed a $1.9 trillion COVID-19 relief bill, the American Rescue Plan Act of 2021, early Saturday. The Senate will now consider the legislation.


RegMed Investors’ (RMi) pre-open: “a new month, rotating with a sentiment boost. The CDC and Prevention advisory panel voted unanimously Sunday to recommend the use of Johnson & Johnson’s (JNJ) one-shot Covid-19 vaccine for people 18 years of age and older. The company expects to ship out 4 million of doses initially.” …


Pre-open indication results:  8 HITs < SELL: Biostage (BSTG -$0.01 with 1,838 shares traded); BUY: Applied Genetic Technologies (AGTC +$0.43), CRISPR Therapeutics (CRSP +$4.56), Editas Medicine (EDIT +$3.03), Intellia Therapeutics (NTLA +$3.57), Voyager Therapeutics (VYGR +$0.30); SELL: Precigen (PGEN -$0.24), Mesoblast (MESO -$0.00) and 2 MISS: BUY: bluebird bio (BLUE -$1.02), Global Blood Therapeutics (GBT +$1.88)


RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions …

  • Monday opened positive at 26/6, 2 flat and 1 acquired, stayed positive at the mid-day to 26/6, 2 flat and 1 acquired, closing positive at 27/6, 1 flat and 1 acquired;
  • Friday opened negative at 4/27, 3 flat and 1 acquired, flipped positive at the mid-day to 18/15, 1 flat and 1 acquired, closing positive at 18/15, 1 flat and 1 acquired;


There are clear winners — and losers — heading into the second month and Q1 of 2021.

Jumping with share pricing momentum:

  • Fate Therapeutics (FATE), CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), Editas Medicine (EDIT) Sage Therapeutics (SAGE) to name 5 of the 27 inclining of the 35 covered

Hammered in today’s market:

  • ReNeuron (RENE.L), bluebird bio (BLUE), Precigen (PGEN), Pluristem (PSTI), Vericel (VCEL), Bellicum Pharmaceuticals (BLCM) to name 6 of the 6 declining of the 35 covered


Key metrics:

  • Sector volume was LOW with 1 of the 27-upside having higher than the 3-month average volume with the increased volume of 2 of 6-downside having higher than the 3-month average volume;
  • Monday’s percentage (%) of the 27-upside were +0.44% (ALNY) to +8.46% (AGTC) while the 6-downside ranges from -0.23% (VCEL) to -5.41% (RENE.L);


Monday’s (10 of 27) incline

  • Fate Therapeutics (FATE +$6.89 after Friday’s +$3.45);
  • CRISPR Therapeutics (CRSP +$4.56 after Friday’s -$1.59);
  • Intellia Therapeutics (NTLA +$3.57 after Friday’s +$2.99);
  • Editas Medicine (EDIT +$3.03 after Friday’s -$0.90);
  • Sage Therapeutics (SAGE +$2.71 after Friday’s +$1.55);
  • Global Blood Therapeutics (GBT +$1.88 after Friday’s -$0.90);
  • Ionis Pharmaceuticals (IONS +$1.65 after Friday’s -$1.01);
  • Regenxbio (RGNX +$1.60 after Friday’s +$0.93);
  • BioLife solutions (BLFS +$1.45);
  • uniQure NV (QURE +$1.35 after Friday’s -$0.30);

Monday’s (6 of 6) decliners:

  • ReNeuron (RENE.L -$6.00 after Friday’s -$2.00);
  • bluebird bio (BLUE -$1.02);
  • Precigen (PGEN -$0.24);
  • Pluristem (PSTI -$0.13);
  • Vericel (VCEL -$0.11 after Friday’s +$0.71);
  • Biostage (BSTG -$0.01 after Friday’s -$0.15);

Closing 1 – Mesoblast (MESO), and 1 - Stemline Therapeutics (STML – acquired)


Sentiment and COVID-19 infections:

  • Johnson & Johnson (JNJ) has begun shipping out nearly 4 million doses of its Covid-19 vaccine

Infection cases <Million>: never to forget …

  • Monday 28.61 M cases,
  • Monday’s death rate totaled 513,510 <Johns Hopkins University>



The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Monday, the IBB closed up +1.73% and XBI closed up +2.43%
  • Friday, the IBB closed down -0.14% and XBI closed up +0.76%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Monday was down -4.60points or -16.46% at 23.25
  • Friday was down -0.94 points or -3.25% at 27.95

Upside volume: low

  • Monday: 1 out of the 27-upside had higher than the 3-month average volume;
  • Friday: 6 out of the 18-upside had higher than the 3-month average volume;

Downside volume: low

  • Monday: 2 out of the 6-downside had higher than the 3-month average volume;
  • Friday: 5 out of the 15-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: % and pricing drop

  • Monday’s percentage (%) of the 27-upside were +0.44% (ALNY) to +8.46% (AGTC) while the 6-downside ranges from -0.23% (VCEL) to -5.41% (RENE.L);
  • Friday’s percentage (%) of the 18-upside were +0.48% (PSTI) to +10.60% (BLUE) while the 15-downside ranges from -0.42% (VSTM) to -8.99% (VYGR);


March, the 3rd month of Q1/21:

Monday (3/1) closed positive with 27 advancers, 6 decliners, 1 flat and 1 acquired


The BOTTOM LINE: I am STILL sending up a red flag on stock pricing until earnings’’ season completes its run.

There is always a shift going-on however, these last two (2) months continues to leave me … QUESTIONING staying longer than a WEEK as I have said recently - my horizon on Monday is to meet on Friday.

As to earnings’ season: “Again, “forewarned … earnings LPS (loss-per-share) season is upon us – my advice, trim and skim … if one can!”


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.